Our top pick for
Nabriva Therapeutics plc is a biotechnology business based in the US. Nabriva Therapeutics shares (NBRV) are listed on the NASDAQ and all prices are listed in US Dollars. Nabriva Therapeutics employs 162 staff and has a trailing 12-month revenue of around USD$2.9 million.
|52-week range||USD$1.84 - USD$15.441|
|50-day moving average||USD$2.8818|
|200-day moving average||USD$4.2687|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.881|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$2.9 million|
|Gross profit TTM||USD$-17,004,000|
|Return on assets TTM||-59.51%|
|Return on equity TTM||-198.02%|
|Market capitalisation||USD$40.7 million|
TTM: trailing 12 months
There are currently 1.3 million Nabriva Therapeutics shares held short by investors – that's known as Nabriva Therapeutics's "short interest". This figure is 75.5% up from 728,638 last month.
There are a few different ways that this level of interest in shorting Nabriva Therapeutics shares can be evaluated.
Nabriva Therapeutics's "short interest ratio" (SIR) is the quantity of Nabriva Therapeutics shares currently shorted divided by the average quantity of Nabriva Therapeutics shares traded daily (recently around 1.1 million). Nabriva Therapeutics's SIR currently stands at 1.17. In other words for every 100,000 Nabriva Therapeutics shares traded daily on the market, roughly 1170 shares are currently held short.
However Nabriva Therapeutics's short interest can also be evaluated against the total number of Nabriva Therapeutics shares, or, against the total number of tradable Nabriva Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nabriva Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Nabriva Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0609% of the tradable shares (for every 100,000 tradable Nabriva Therapeutics shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nabriva Therapeutics.
Find out more about how you can short Nabriva Therapeutics stock.
We're not expecting Nabriva Therapeutics to pay a dividend over the next 12 months.
Nabriva Therapeutics's shares were split on a 1:10 basis on 3 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nabriva Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Nabriva Therapeutics shares which in turn could have impacted Nabriva Therapeutics's share price.
Over the last 12 months, Nabriva Therapeutics's shares have ranged in value from as little as $1.84 up to $15.441. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nabriva Therapeutics's is 1.9077. This would suggest that Nabriva Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.